MaxCyte Q4 core revenue +20%, total rev -45% on milestone comp; FY2025 core growth 8-15%

MAXCYTE, INC.

Q4 2024 total revenue $8.7M (-45% YoY); core revenue ex-milestones $8.6M (+20%); net loss $10.6M vs $5.3M.
FY2024 total revenue $38.6M (-6%); core revenue $32.5M (+9%); gross margin 82%; net loss $41.1M vs $37.9M.
Ended 2024 with $190.3M cash; 28 active SPLs (up from 23), 18 clinical SPL programs, 1 commercial.
2025 guidance: core revenue growth 8-15% (incl SeQure Dx); SPL rev ~$5M; cash target $160M year-end.
Signed record six SPLs in 2024; added TG Therapeutics early 2025; SeQure Dx acquisition integrated.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.